Publicaciones en las que colabora con María Jesús Garrido Cid (36)

2024

  1. Foxp3 inhibitory peptide encapsulated in a novel CD25-targeted nanoliposome promotes efficient tumor regression in mice

    Acta Pharmacologica Sinica

2023

  1. Assessment of Clinical Response to V937 Oncolytic Virus After Intravenous or Intratumoral Administration Using Physiologically-Based Modeling

    Clinical Pharmacology and Therapeutics, Vol. 114, Núm. 3, pp. 623-632

2021

  1. Dual activity of PD-L1 targeted Doxorubicin immunoliposomes promoted an enhanced efficacy of the antitumor immune response in melanoma murine model

    Journal of Nanobiotechnology, Vol. 19, Núm. 1

  2. Mechanistic Modeling of a Novel Oncolytic Virus, V937, to Describe Viral Kinetic and Dynamic Processes Following Intratumoral and Intravenous Administration

    Frontiers in Pharmacology, Vol. 12

  3. Modulation of intratumoural myeloid cells, the hallmark of the anti-tumour efficacy induced by a triple combination: tumour-associated peptide, TLR-3 ligand and α-PD-1

    British Journal of Cancer, Vol. 124, Núm. 7, pp. 1275-1285

  4. Semi-mechanistic model for the antitumor response of a combination cocktail of immuno-modulators in non-inflamed (Cold) tumors

    Cancers, Vol. 13, Núm. 20

2020

  1. Drug Exposure to Establish Pharmacokinetic–Response Relationships in Oncology

    Clinical Pharmacokinetics, Vol. 59, Núm. 2, pp. 123-135

  2. Modificaciones farmacocinéticas y farmacodinámicas en el anciano

    Tratado de medicina geriátrica: fundamentos de la atención sanitaria a los mayores (Elsevier), pp. 72-82

2019

  1. A new immune-nanoplatform for promoting adaptive antitumor immune response

    Nanomedicine: Nanotechnology, Biology, and Medicine, Vol. 17, pp. 13-25

  2. Pharmacokinetic and pharmacodynamic modelling in anaesthesia

    Personalized Anaesthesia: Targeting Physiological Systems for Optimal Effect (Cambridge University Press), pp. 14-28

2017

  1. Commentary on Pharmacometrics for Immunotherapy

    CPT: Pharmacometrics and Systems Pharmacology, Vol. 6, Núm. 1, pp. 8-10

  2. Population pharmacokinetics of clarithromycin in Mexican hospitalized patients with respiratory disease: Evidence for a reduced clearance

    International Journal of Pharmacology, Vol. 13, Núm. 1, pp. 54-63

2016

  1. Correlation between anti-PD-L1 tumor concentrations and tumor-specific and nonspecific biomarkers in a melanoma mouse model

    Oncotarget, Vol. 7, Núm. 47, pp. 76891-76901

  2. EGF-liposomes promote efficient EGFR targeting in xenograft colocarcinoma model

    Nanomedicine, Vol. 11, Núm. 5, pp. 465-477

  3. Population Pharmacokinetic Analysis of Lanreotide Autogel®/Depot in the Treatment of Neuroendocrine Tumors: Pooled Analysis of Four Clinical Trials

    Clinical Pharmacokinetics, Vol. 55, Núm. 4, pp. 461-473

2015

  1. Semimechanistic cell-cycle type-based pharmacokinetic/pharmacodynamic model of chemotherapy-induced neutropenic effects of diflomotecan under different dosing schedules

    Journal of Pharmacology and Experimental Therapeutics, Vol. 354, Núm. 1, pp. 55-64

2014

  1. Review on modeling anti-antibody responses to monoclonal antibodies

    Journal of Pharmacokinetics and Pharmacodynamics, Vol. 41, Núm. 5, pp. 523-536

2012

  1. Application of different methods to formulate PEG-liposomes of oxaliplatin: Evaluation in vitro and in vivo

    European Journal of Pharmaceutics and Biopharmaceutics, Vol. 81, Núm. 2, pp. 273-280

  2. Pharmacodynamic modeling of the effects of lanreotide autogel on growth hormone and insulin-like growth factor 1

    Journal of Clinical Pharmacology, Vol. 52, Núm. 4, pp. 487-498

2010

  1. A semi-physiological-based pharmacokinetic/pharmacodynamic model to describe the effects of topotecan on B-lymphocyte lineage cells

    Pharmaceutical Research, Vol. 27, Núm. 3, pp. 431-441